Varivax Purple Book BLA 103552

BLA number
103552
Proprietary names
Varivax
Proper names
Varicella Virus Vaccine Live
Applicant
Merck Sharp & Dohme LLC
Center
CBER
First observed release
2020-08-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001VarivaxVaricella Virus Vaccine Live351(a)NLT 1350PFU/.5MLFor InjectionSubcutaneousSingle-Dose VialRxLicensed1995-03-17
002VarivaxVaricella Virus Vaccine Live351(a)NLT 1350PFU/.5MLFor InjectionIntramuscularSingle-Dose VialRxLicensed2023-02-27

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2023-03-01U001Varivax351(a)RxMerck Sharp & Dohme LLC
2023-03-01N002Varivax351(a)RxMerck Sharp & Dohme LLC
2021-05-01U001Varivax351(a)RxMerck Sharp & Dohme Corp.
2020-08-01R001Varivax351(a)RxMerck Sharp & Dohme Corp.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2023-03-01002Varivax351(a)RxLicensed2023-02-27
2020-08-01001Varivax351(a)RxLicensed1995-03-17